MG-132

MG-132 is an inhibitor of proteasome with IC50 of 100 nM in a cell-free assay, and also inhibits calpain with IC50 of 1.2 μM.

Price Stock Quantity  
In DMSO USD 100 In stock
USD 50 In stock
USD 170 In stock
USD 470 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

MG-132 Chemical Structure

MG-132 Chemical Structure
Molecular Weight: 475.62

Validation & Quality Control

Product Use Citation(40)

Customer Product Validation(6)

Quality Control & MSDS

Related Compound Libraries

MG-132 is available in the following compound libraries:

Proteasome Inhibitors with Unique Features

Product Information

  • Compare Proteasome Inhibitors
    Compare Proteasome Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description MG-132 is an inhibitor of proteasome with IC50 of 100 nM in a cell-free assay, and also inhibits calpain with IC50 of 1.2 μM.
Targets Proteasome [1]
(Cell-free assay)
IC50 100 nM
In vitro MG-132 displays >1000 times more activity than ZLLal in inhibiting the ZLLL-MCA-degrading activity of 20S proteasome with IC50 of 100 nM versus 110 μM. MG-132 also inhibits calpain with IC50 of 1.2 μM. MG-132 induces neurite outgrowth in PC12 cells at an optimal concentration of 20 nM, displaying 500 times more potency than ZLLal. [1] MG-132 (10 μM) potently inhibits TNF-α-induced NF-κB activation, interleukin-8 (IL-8) gene transcription, and IL-8 protein release in A549 cells by inhibition of proteasome-mediated IκBα degradation. [2] MG-132 treatment potently induces p53-dependent apoptosis in KIM-2 cells by 26S proteasome inhibition. [3] Unlike BzLLLCOCHO or PS-341, MG-132 treatment results in weak inhibition of the chymotrypsinlike (CT-L) and peptidylglutamyl peptide hydrolysing (PGPH) activities of the 26S proteasome, whereas multiple myeloma cells (U266 and OPM-2) are more sensitive to induction of apoptosis by MG-132 than BzLLLCOCHO. [4] MG-132 (1 μM) sensitizes TRAIL-resistant prostate cancer cells by activating the AP-1 family members c-Fos and c-Jun, which, in turn, repress the antiapoptotic molecule c-FLIP(L). [5] MG-132 significantly enhances the ability of inositol hexakisphosphate (IP6) to reduce cellular metabolic activity in both PC3 and DU145 androgen-independent prostate cancer (AIPCa) cell lines. [6]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity Description
LPS-stimulated RAW264.7 cellsMn7oSpVv[3Srb36gRZN{[Xl?NHjFZY8zPSEQvF2=M3jm[GROW09?M4W0bGlvcGmkaYTzJI5qfHKrYzDvfIll\SCycn;keYN1cW:wIIfpeIghUUN3MDDv[kAxNjFizszN
HL-60NF3WXXJEgXSxdH;4bYMhSXO|YYm=NUnXSJQ1PDBizszNNF2zN2c1QCCqNHvkNVdFVVORNVS3ZVNlUUN3MEyxNEDPxE1?
SMMC-7721MVLDfZRwfG:6aXOgRZN{[Xl?M3rOcVQxKM7:TR?=M4nnV|Q5KGh?M4DrRWROW09?NYTOTINWUUN3ME23MlEh|ryP
A-549NW\aNXEyS3m2b4TvfIlkKEG|c3H5M{LWfVQxKM7:TR?=MXS0PEBpMVXEUXNQNYm5XHhCUUN3MEyxNEDPxE1?
MCF-7M1;zVmN6fG:2b4jpZ{BCe3OjeR?=NF;OZYo1OCEQvF2=M1HZT|Q5KGh?MomwSG1UVw>?NYHKfW1bUUN3ME23MlMh|ryP
SW-480MVvDfZRwfG:6aXOgRZN{[Xl?MX[0NEDPxE1?NXLmdXl6PDhiaB?=MXjEUXNQNUL2VJloUUN3ME20JO69VQ>?
NCI-H929NVvFc5U6S3m2b4TvfIlkKEG|c3H5MkK4NUDPxE1?MUe3NkBpNHrxbolFVVORMnTKTWM2OD1yLkG3JO69VQ>?
293TNVzPR2JVS3m2b4TvfIlkKEG|c3H5NYqzRpZVOTBizszNMXW3NkBpMUfEUXNQM1LjUWlEPTB:MjFOwG0>
293TM2jzcmZ2dmO2aX;uJGF{e2G7NIGybFkyOCEQvF2=MlvYNlQhcA>?MXTEUXNQNFW3XVhOd2SncnH0[Yx6KGmwZIXj[ZMhcGWjdD3zbI9kcyBi
HeLaNIq2NWxMcW6jc3WgRZN{[Xl?MYexNEDPxE1?MmD6NUBpMoi1SG1UVw>?M3nV[Wlv\HWlZYOgVGFTWCClbHXheoFo\SCkeTDpcohq[mm2aX7nJJBzd3OnYYPvcYUh[WO2aY\peJk>
MDA-MB-231NXXDO|h1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUKxJO69VQ>?NUiwRXplPzJiaB?=NHvvXWdFVVORM1;1[2lEPTB;MD6xPEDPxE1?
MCF-7NUTxdZVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoK2NUDPxE1?NYfHUYZyPzJiaB?=MWHEUXNQM2mwTWlEPTB;MD6xN{DPxE1?
MCF10AMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUXo[|U6OSEQvF2=M3;LTVczKGh?M{DhW2ROW09?NFiyfFBKSzVyPUCuNlkh|ryP
HEK-293MXzLbY5ie2ViQYPzZZk>MWmyJIFv\CB{MDFOwG0>MoK3NkBpNWHF[HFtTE2VTx?=M4r0Z2lvcGmkaYTzJGNpXC2OIHHjeIl3cXS7IIfpeIghUUN3MDDv[kA6KG6PIB?=
Calu6MVnGeY5kfGmxbjDBd5NigQ>?MkSwNVAh|ryPMk\4NVghcA>?NHm1[pZFVVORNVL3TIN{W2mpbnnmbYNidnSueTDhZ4N2dXWuYYTld{BnemG2YYjpckBxemWldYLzc5I>
IFN-gamma-induced RAW264.7NFjmcpdHfW6ldHnvckBCe3OjeR?=MWTEUXNQNW\sSmRHUW6qaXLpeJMhdmm2cnnjJI95cWSnIIDyc4R2[3Srb36ge4l1cCCLQ{WwJI9nKDBwMEe3JO69VQ>?
IPC227FMnPIR5l1d3SxeHnjJGF{e2G7MV6xJO69VQ>?M3XkbFQ5KGh?M{fSNWROW09?NHfPfVRKSzVyPUCuNFc4KM7:TR?=
Hepa-1c1c7Mn7RSpVv[3Srb36gRZN{[Xl?NILi[oEzPSEQvF2=MYe2JIg>MlLRSG1UVw>?NHjLTJdKdmO{ZXHz[ZMhVnKoMjDwdo91\WmwIHzleoVt
COS-7M4L5b2N6fG:2b4jpZ{BCe3OjeR?=NWXXe4ptOTBizszNNYC1R4VCTE2VTx?=NVnsWXFGUUN3MEyxNEDPxE1?
HuH-7NGDSbohEgXSxdH;4bYMhSXO|YYm=M2TnflExKM7:TR?=MYjEUXNQNXnCZZNYUUN3MEyxNEDPxE1?
OCI-Ly3MoLvSpVv[3Srb36gRZN{[Xl?Mo[5NVAh|ryPwrC=MlXLOEBpM4H2SWROW09?M4TZR2lv\HWlZYOgbJVu[W5iSXvhdJBiSmGucHjhJJN1[WKrbHn6ZZRqd25id3n0bEBGSzVyIH;mJFEh|ryP
A2780 cDDPM2DsbWFxd3C2b4Ppd{BCe3OjeR?=MYWyOEBpNGrxc5VFVVORM4K3eWlv\HWlZYOgZZBweHSxc3nzJIJ6KGmwaHnibZRqdmdiUGTFUkBl\We{YXTheIlwdg>?
LPS-stimulated RAW264.7 cellsM2fqVGZ2dmO2aX;uJGF{e2G7MVLEUXNQMYfJcohq[mm2czDOSk1s[XCyYVKgSG5CKGKrbnTpcoc>
PC12MlvqSpVv[3Srb36gRZN{[Xl?NUP5WFlYOTByIN88UeKhMXSyOEBpM4\obGROW09?M4rrZWlvcGmkaYTzJFYuV0iGQT2gZY5lKEh{T{KtbY5lfWOnZDDjfZRwfG:6aXPpeJk>
PC3MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnGxNlAh|ryPM2jsVlQ5KGh?NHT0RWVFVVORM3LuSmlEPTB;MD62JO69VQ>?
LP-1M4LZSGFxd3C2b4Ppd{BCe3OjeR?=M37oc|MxOCCwTR?=NU\JVWxPOjRiaB?=M2DNNGROW09?MkTtTY5lfWOnczDhdI9xfG:|aYOgZpkhcW6lcnXhd4lv\yClbHXheoVlKFCDUmCgcIV3\WxiYX7kJJJm\HWlaX7nJG1kdC1zIIDyc5RmcW5ibHX2[Yw>
ES6NUnUZnhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV7SRZl7UUN3ME2wMlAyOzB4IN88US=>
A101DM1fkV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVTJR|UxRTBwMEOyO|kh|ryP
OCUB-MNGjLWpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX\JR|UxRTBwMEO3N|ch|ryP
LB2518-MELMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX\JR|UxRTBwMEO3OkDPxE1?
SH-4M1u0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnG4TWM2OD1yLkC0N|Eh|ryP
KNS-42NXrJ[pJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkCxTWM2OD1yLkC0OFQyKM7:TR?=
DSH1MnnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MU\JR|UxRTBwMEWyPFkh|ryP
NTERA-S-cl-D1MnLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX;JR|UxRTBwMEW3O|Ih|ryP
D-542MGMmLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVLTfYRtUUN3ME2wMlA2QTV5IN88US=>
KS-1NF;nU2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHj5TpJKSzVyPUCuNFY1PThizszN
BL-41M3XKXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkjOTWM2OD1yLkC2PVQ4KM7:TR?=
LXF-289M3jwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MULJR|UxRTBwMEewOlYh|ryP
D-247MGNHTqV5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWPZdZBDUUN3ME2wMlA4OjB7IN88US=>
MMAC-SFNYnZU2xLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG\VOnVKSzVyPUCuNFczPjhizszN
CP66-MELNVXFVGdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV3JR|UxRTBwMEe1JO69VQ>?
LB771-HNCMV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYjuWFVvUUN3ME2wMlA5ODN4IN88US=>
no-10MofYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml;pTWM2OD1yLkC4PVA6KM7:TR?=
A388MnrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGP4eYZKSzVyPUCuNFkxPjVizszN
OPM-2M3PpXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M33Ve2lEPTB;MD6xNFQ4PCEQvF2=
OVCAR-4NUXuTpFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkHsTWM2OD1yLkGwPVM5KM7:TR?=
HOP-62M{X3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3GyPGlEPTB;MD6xNFk1QSEQvF2=
ML-2M3e1NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MknSTWM2OD1yLkGxPFA3KM7:TR?=
UACC-257MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEXReHpKSzVyPUCuNVE6OjdizszN
NEC8NHGxXIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH6wZWxKSzVyPUCuNVE6QTVizszN
ONS-76M1\iXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUTQdJBYUUN3ME2wMlEzQTN3IN88US=>
KE-37MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTBwMUOyO|gh|ryP
HT-144NYTIOZVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXnFWJlGUUN3ME2wMlE{QDl3IN88US=>
LB2241-RCCMoC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHTBb4xKSzVyPUCuNVQzPDdizszN
TE-5NGX6bHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MorFTWM2OD1yLkG0Nlc5KM7:TR?=
KINGS-1Ml7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV\aem5ZUUN3ME2wMlE1PzlizszN
NCI-H69M1zxd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTBwMUWxOFEh|ryP
CAS-1M{PjdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFnQeIlKSzVyPUCuNVU1QDJizszN
D-263MGM{THfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV3rTWZ2UUN3ME2wMlE3ODB4IN88US=>
A253NITZcIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4HhbmlEPTB;MD6xOlEzQCEQvF2=
PF-382NHr4WphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVjJR|UxRTBwMU[3NFYh|ryP
CESSM37q[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYrJR|UxRTBwMUewOkDPxE1?
MZ2-MELM{\SUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUKwelhVUUN3ME2wMlE4PTV7IN88US=>
HELMVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF\aO3hKSzVyPUCuNVg2OTdizszN
D-392MGNYG4c3ViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4T1bGlEPTB;MD6xPVEyPSEQvF2=
SK-LMS-1NGq1[ZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX;CV|k6UUN3ME2wMlE6OzB|IN88US=>
GI-ME-NM2T3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYfJR|UxRTBwMUmzNFYh|ryP
LB831-BLCMlz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mmq3TWM2OD1yLkG5N|Qh|ryP
DU-4475MoPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmL6TWM2OD1yLkG5OlU5KM7:TR?=
IST-SL1NVK5S2FvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXzyVo9nUUN3ME2wMlIxODl2IN88US=>
GAKNFXab|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRTBwMkC1N|Qh|ryP
EW-1M4TYWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlrXTWM2OD1yLkKxNFQ4KM7:TR?=
LAMA-84MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRTBwMkG4OVEh|ryP
SK-UT-1NWf6b|V4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXjJR|UxRTBwMkKwOFkh|ryP
VA-ES-BJMkHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUTLOYRGUUN3ME2wMlIzOjV5IN88US=>
ACNNEHrVohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4\6V2lEPTB;MD6yNlY{QCEQvF2=
SK-PN-DWMVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH[5elNKSzVyPUCuNlMyQSEQvF2=
HD-MY-ZNVKz[lNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYDJR|UxRTBwMkOzNFMh|ryP
LB373-MEL-DNIr3R45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWTJR|UxRTBwMkSxPVgh|ryP
COLO-829NYLhWpFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVXnPJB3UUN3ME2wMlI1OjV5IN88US=>
ES8NVX6WnRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3rjR2lEPTB;MD6yOFc3OyEQvF2=
RXF393M3;yZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHLJNVBKSzVyPUCuNlUxOTVizszN
TK10MmLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3v0RmlEPTB;MD6yOVQ{PSEQvF2=
LOUCYNXTkN2poT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEez[GNKSzVyPUCuNlU1PTZizszN
MZ7-melNX;LT4Z3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkjNTWM2OD1yLkK2N|c1KM7:TR?=
CP67-MELMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYTJR|UxRTBwMk[3N{DPxE1?
C2BBe1M{PoRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoTlTWM2OD1yLkK3PVA4KM7:TR?=
K052NE\EWVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUnjSVFiUUN3ME2wMlI5QTlizszN
MOLT-16MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYDJR|UxRTBwMkm1NlQh|ryP
KNS-81-FDNHHN[FVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3;0VmlEPTB;MD6zNFMzOyEQvF2=
CMKNX62dIVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXe0Oo0zUUN3ME2wMlMyOTJizszN
LAN-6M2PwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3K3T2lEPTB;MD6zNVMh|ryP
KLEMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoTDTWM2OD1yLkOxN|A3KM7:TR?=
NCCITMmLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkjoTWM2OD1yLkOxO|g{KM7:TR?=
HHNV7HU2RXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mm\2TWM2OD1yLkOyPFk4KM7:TR?=
TE-8M16xXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4TxOmlEPTB;MD6zOFI4QSEQvF2=
GDM-1NU\re3Z{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1y2Z2lEPTB;MD6zOVExPCEQvF2=
NCI-H747NYPn[2gzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkP3TWM2OD1yLkO3NVA{KM7:TR?=
NCI-H1092MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{nRT2lEPTB;MD6zPFg1PCEQvF2=
8-MG-BAMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIH3WZBKSzVyPUCuN|k5OzdizszN
NB17M3nsZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGjKOJpKSzVyPUCuOFI6PyEQvF2=
LC4-1NWDRbpVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHvyUmFKSzVyPUCuOFM3ODdizszN
TE-1NUPVR4FVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXy0fJVkUUN3ME2wMlQ2OTF7IN88US=>
KALS-1NG[wZXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NITWfnpKSzVyPUCuOFY2QDRizszN
CCRF-CEMMlT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3jReWlEPTB;MD60O|Y4PCEQvF2=
OS-RC-2M1[0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml\jTWM2OD1yLkS3PVczKM7:TR?=
A704M1rOWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mnq1TWM2OD1yLkS4OlkzKM7:TR?=
BB49-HNCNVLOblJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXKybW1vUUN3ME2wMlQ6ODl4IN88US=>
EVSA-TNY\4NJIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTBwNEm5NVEh|ryP
Mo-TM3HiPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVfteJl{UUN3ME2wMlUyPzZ{IN88US=>
MONO-MAC-6MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIq1TWFKSzVyPUCuOVM3OTFizszN
BB65-RCCM17Ke2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXSzeY43UUN3ME2wMlU3QDFzIN88US=>
NCI-H1882NVPKNoc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkPDTWM2OD1yLkW5NFM3KM7:TR?=
TE-9NFzkNJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4Wzb2lEPTB;MD62NVA{OyEQvF2=
NCI-H2126NIftWWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYjzeVFUUUN3ME2wMlYzPjZ7IN88US=>
SF268NVHQcnl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXHPdIhxUUN3ME2wMlY2PjRzIN88US=>
SW872MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn;mTWM2OD1yLk[1O|I6KM7:TR?=
LS-513NUjKXIFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3n6emlEPTB;MD62Olc2OSEQvF2=
NCI-H1355MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF\XfGZKSzVyPUCuOlg3OTlizszN
BL-70NIiyfYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4LTOWlEPTB;MD62PVM5QCEQvF2=
NCI-SNU-5M3fSXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIDsc4VKSzVyPUCuOlk2PDVizszN
SNU-C2BNV7OUGtnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkjoTWM2OD1yLkewO|M6KM7:TR?=
GB-1MlnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmT4TWM2OD1yLkeyNVI1KM7:TR?=
CTB-1NFv2eVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWnJR|UxRTBwN{e5OVUh|ryP
BeckerNX\aTlV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn2xTWM2OD1yLke5OlIyKM7:TR?=
KM12MmP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUnJR|UxRTBwOEW0OlYh|ryP
ES7MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGjo[5dKSzVyPUCuPFk3PSEQvF2=
COLO-684NV;pPWV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnzVTWM2OD1yLkmwOlU5KM7:TR?=
HCC2998NEC1ZolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYXzOGltUUN3ME2wMlk{QDV2IN88US=>
TE-10NWLWXGNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnPDTWM2OD1yLkm2OFMh|ryP
SF126MmrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkHCTWM2OD1yLkm4PVcyKM7:TR?=
EKVXM4TJc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEi0U3ZKSzVyPUGuNFM1PDJizszN
KARPAS-45MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3PZc2lEPTB;MT6wOFAyPiEQvF2=
KGNNYjpUFlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1nOOWlEPTB;MT6wOVA1PSEQvF2=
ES1MkjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHntfnVKSzVyPUGuNFc6OjFizszN
L-540NFf6cZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUL6N4FMUUN3ME2xMlEyQDN7IN88US=>
KURAMOCHIMlztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{T1VGlEPTB;MT6xNlM4PCEQvF2=
LU-65NHzLSY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX\DVJVxUUN3ME2xMlEzPzV|IN88US=>
MFH-inoNIn0VJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIT2U5JKSzVyPUGuNVc2ODFizszN
NCI-H23MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWTJR|UxRTFwMkC0NUDPxE1?
IA-LMMonUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUL6d4QxUUN3ME2xMlI1OTF4IN88US=>
PSN1M4j2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGLZ[ZNKSzVyPUGuNlcxOTZizszN
NCI-H719NULmUoJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWXJR|UxRTFwMke0NVEh|ryP
SW684MnPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV;jT4lOUUN3ME2xMlI5PjV7IN88US=>
HCE-4MlL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF;1emRKSzVyPUGuN|AzOjFizszN
EW-16M1HSemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFO3d|RKSzVyPUGuN|E{PDdizszN
NCI-H128NEX1eWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4P2XmlEPTB;MT6zOVgyPCEQvF2=
HC-1MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MknYTWM2OD1zLkO4NVch|ryP
IST-MES1MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlTTTWM2OD1zLkSwNlA5KM7:TR?=
RajiMn3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2TwfmlEPTB;MT60NVg2KM7:TR?=
DMS-114NG[2d5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUHtXY1KUUN3ME2xMlQ1PTN7IN88US=>
GI-1MnnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mo\lTWM2OD1zLkS3NVMyKM7:TR?=
NCI-H2081NYi1N2hzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MojxTWM2OD1zLkW1NVk3KM7:TR?=
LC-1FNEDnZYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXHhZYwzUUN3ME2xMlU2OTl6IN88US=>
NCI-H2227NV\OdlJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3zXUGlEPTB;MT62NVU3OSEQvF2=
D-502MGM{LsUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXnBdWFlUUN3ME2xMlY4OjFzIN88US=>
NCI-H2141MmXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkK4TWM2OD1zLk[3N|E4KM7:TR?=
LS-411NM2XSXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MU\JR|UxRTFwNkm4NFch|ryP
SU-DHL-1MkjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH7LSoFKSzVyPUGuO|EzQDFizszN
BB30-HNCNGDjOWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4HSTWlEPTB;MT63NlY5PSEQvF2=
TE-15NFrucmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVLxdWxjUUN3ME2xMlkzOzd|IN88US=>
JVM-3MnywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2PSUWlEPTB;MT65N|kxPCEQvF2=
IST-SL2MoLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{fKTWlEPTB;Mj6wNVI2OiEQvF2=
EW-18MnnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFTrdZpKSzVyPUKuNFI{OzdizszN
DJM-1NFfPRYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVrJR|UxRTJwMEK1OVIh|ryP
no-11MoHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWDJR|UxRTJwMEOxNFQh|ryP
QIMR-WILMm\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlKwTWM2OD1{LkG2O|YzKM7:TR?=
MC-CARMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1fXPGlEPTB;Mj6yNlk2KM7:TR?=
KM-H2MoHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmLpTWM2OD1{LkK5NFQ{KM7:TR?=
ECC12M1LOc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHztOY1KSzVyPUKuN|c6PCEQvF2=
HCE-TMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUfJR|UxRTJwNES4PFMh|ryP
MFM-223M1;2OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYHGToxNUUN3ME2yMlUxQDdzIN88US=>
SW982MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWHJR|UxRTJwNUG0PEDPxE1?
KG-1NEOwZYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUHJR|UxRTJwOEi3PVEh|ryP
ES4M2PkTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{K4W2lEPTB;Mz6wOlEyOSEQvF2=
SCC-3M36xbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MojqTWM2OD1|LkGwPFQ5KM7:TR?=
RH-1NVTIT4RKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFO2PZZKSzVyPUOuN|g4PDhizszN
NCI-H748MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmnzTWM2OD1|LkS0NlY3KM7:TR?=
HCC2218MlTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkfsTWM2OD1|LkS2PVM4KM7:TR?=
MEG-01NE\i[5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUXJR|UxRTNwNUm2PEDPxE1?
NB12NX\4bHRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4C3OmlEPTB;Mz61PVg5QCEQvF2=
SNB75MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{[1PWlEPTB;Mz62NFExOyEQvF2=
KMS-12-PEMnXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVPJR|UxRTNwNke3NlMh|ryP
SKM-1MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmTITWM2OD1|LkexN|c3KM7:TR?=
COLO-320-HSRNV20SGZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHv5R5VKSzVyPUOuO|U3OzRizszN
NKM-1NEDtS45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYTJR|UxRTNwN{ezO|gh|ryP
TE-6NXPFR|c{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MorETWM2OD1|Lkm0OVYyKM7:TR?=
D-336MGNWL0[GlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWnlW3c5UUN3ME20MlAyOTZ4IN88US=>
NCI-H1650MonZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkToTWM2OD12LkG1O|k4KM7:TR?=
ES3NFrwXIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnTPTWM2OD12LkOyPFI1KM7:TR?=
YTNWHORXV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWTJR|UxRTRwM{W0NlQh|ryP
ES5NXfofIZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYLHNoRyUUN3ME20MlQxOjV3IN88US=>
LB647-SCLCNFK5e|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M33KPWlEPTB;ND61OlMxQCEQvF2=
HAL-01NUHZ[oJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MY\JR|UxRTRwNUewN|Qh|ryP
LP-1MknZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2fzOmlEPTB;ND63NlM4OSEQvF2=
BC-1NUni[o06T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEDKOGRKSzVyPUWuNFA1PDdizszN
EB-3NXnCSmx4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX;aRWRrUUN3ME21MlA{ODRzIN88US=>
GT3TKBMlLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTVwMUe2OlIh|ryP
NCI-H209MoXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUTtZ3I4UUN3ME21MlE6OzV{IN88US=>
BT-474M4HRcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXv2SJF2UUN3ME21MlI{OTB{IN88US=>
RKOM1[5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUjhWWNZUUN3ME21MlI{PDJ{IN88US=>
SIMAM4P5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIDoRmhKSzVyPUWuN|A4PjVizszN
RLNH[0WJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFTkWYhKSzVyPUWuN|c2PDFizszN
GCIYM3\nWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkSxTWM2OD13LkS3NlM3KM7:TR?=
Calu-6NIL6TFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVnJR|UxRTVwNkKyJO69VQ>?
ALL-PONH7Jd5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHH3bIhKSzVyPUWuOlM4QTVizszN
ARH-77NV3DWFkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXPJR|UxRTVwNkewPFch|ryP
A4-FukNF:x[IJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoXzTWM2OD14LkC4NVE5KM7:TR?=
NCI-H1581MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3LsWWlEPTB;Nj6yN|g1QSEQvF2=
HUTU-80M1Xkc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGXzbZRKSzVyPU[uN|Y5QTdizszN
TGWM3rW[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH7PcY5KSzVyPU[uOFU2QTNizszN
SK-N-FINH\mbFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NE\z[JBKSzVyPU[uOFU5PTRizszN
U-266NFK2R5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVzJR|UxRTZwNUG5NlYh|ryP
EM-2NEDCT|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHfVV2FKSzVyPU[uOlcxQTlizszN
NMC-G1NVewOItrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MU\JR|UxRTZwN{G4PVUh|ryP
KASUMI-1NWn0SVFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoqzTWM2OD14Lki0O|g4KM7:TR?=
NALM-6NFTCSFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXzJR|UxRTZwOE[3OVQh|ryP
OCI-AML2MkLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2ruUWlEPTB;Nz6wNFMzPiEQvF2=
SHP-77MmrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkjUTWM2OD15LkKyOFMh|ryP
NOMO-1MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGXHRmhKSzVyPUeuNlQzPTRizszN
SK-N-DZM3PKR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVzkVVE{UUN3ME23MlcyODh7IN88US=>
LB1047-RCCMorMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHTCSlVKSzVyPUeuO|IzOzFizszN
MZ1-PCM4rrdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M13kUmlEPTB;Nz64OlU2QCEQvF2=
NB10MnWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4freGlEPTB;Nz65PVU2PiEQvF2=
RL95-2M4fzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRThwMUC4OFIh|ryP
OMC-1NWmzSnA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3jYbmlEPTB;OD61NlE6OSEQvF2=
D-283MEDMmHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV3JR|UxRThwOUG3NVkh|ryP
MC116NFvBXINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHT3Z2FKSzVyPUiuPVc6PCEQvF2=
SJSA-1M3PrWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NILQbYtKSzVyPUmuNFkxQTFizszN
JiyoyeP-2003NVP0OJJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGnNTJhKSzVyPUmuNlk{OTdizszN
IST-MEL1MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHOyS5JKSzVyPUmuO|QyQThizszN
CTV-1M{LzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MU\JR|UxRTFyLkC5O|kh|ryP
NH-12MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHHzOXBKSzVyPUGwMlI1OzNizszN
CA46NYDMfVFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYPJR|UxRTFyLkO2NUDPxE1?
NCI-SNU-1M{\uWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3\4PWlEPTB;MUCuOFk3QSEQvF2=
SCLC-21HM4GxU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYHJR|UxRTFyLk[1PVYh|ryP
EC-GI-10NF:xXIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHPCXFNKSzVyPUGwMlcxOzFizszN
SRM2HrfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYTlRVhWUUN3ME2xNU4xOTh3IN88US=>
NCI-H1648M1mxZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVrJR|UxRTFzLkC5OlUh|ryP
TGBC1TKBMUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHvXT2ZKSzVyPUGxMlQyODJizszN
EW-11MmnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2m1WmlEPTB;MUGuOVE5PiEQvF2=
SK-MM-2MnnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVnPN3NrUUN3ME2xNU45ODZzIN88US=>
NCI-H524M1T0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV62b5lDUUN3ME2xNU46QDJ{IN88US=>
NOS-1MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mk\QTWM2OD1zMj6wN|Q2KM7:TR?=
AM-38MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYjJR|UxRTF{LkW2N|Mh|ryP
A498MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MonrTWM2OD1zMj63NFY6KM7:TR?=
KARPAS-422NHLNN5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVvJR|UxRTF{Lke0PVYh|ryP
LU-139MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MY\JR|UxRTF{LkmwNlYh|ryP
COR-L88NFqye2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV7N[pRiUUN3ME2xNk46Ozh{IN88US=>
K5M4PqZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYrJR|UxRTF{Lkm0OlIh|ryP
NB13M4HGbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MW\JR|UxRTF{Lkm3PFMh|ryP
MRK-nu-1NUjPUGhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3jvfmlEPTB;MUOuNVk2KM7:TR?=
MHH-NB-11Mny1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWHJR|UxRTF|LkK5NFIh|ryP
KU812MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MW\JR|UxRTF|Lk[xNlQh|ryP
TE-12M2XOeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFvySIlKSzVyPUGzMlY6QTRizszN
NCI-N87NWjqWIlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVfJR|UxRTF|LkezOkDPxE1?
EB2Ml7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mni3TWM2OD1zMz64OVA2KM7:TR?=
DBMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4jxfmlEPTB;MUOuPVg5PSEQvF2=
697NX;IU3JpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkXXTWM2OD1zND60OVEyKM7:TR?=
MSTO-211HNUTtN4tmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4PGZ2lEPTB;MUSuO|Q1QCEQvF2=
JVM-2M3Pxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVnCdnNKUUN3ME2xOE44PzN3IN88US=>
COLO-824NFXXV3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3vwS2lEPTB;MUSuO|k6PCEQvF2=
BC-3MojwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{DNOWlEPTB;MUWuN|k5KM7:TR?=
BOKUMkDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MofDTWM2OD1zNT65OlA5KM7:TR?=
GOTONWHGTVVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIXIPZBKSzVyPUG2Mlk3OTdizszN
HCC2157MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWjJR|UxRTF5LkS3OVUh|ryP
LS-1034M3jQVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn7OTWM2OD1zNz62PFE5KM7:TR?=
CAL-148MknYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlHsTWM2OD1zNz65O|k3KM7:TR?=
MOLT-4NVvv[lc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX;sPZFWUUN3ME2xPE45OjB6IN88US=>
DaudiMXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnH4TWM2OD1zOD65NlMyKM7:TR?=
J-RT3-T3-5MoTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVTJR|UxRTF7LkSwOlYh|ryP
KMOE-2NFTnTIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NU\pOIlVUUN3ME2xPU43PDh{IN88US=>
HL-60NHr6Oo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{HIO2lEPTB;MkCuNVk3PSEQvF2=
P31-FUJNHjrb2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXrWZ2ljUUN3ME2yNE41PzV|IN88US=>
IM-9NUnQZWExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWfVdHVuUUN3ME2yNE43OjJ2IN88US=>
HDLM-2M1;ZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnrVTWM2OD1{MD64PFIyKM7:TR?=
NCI-H1304MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYjRSVFVUUN3ME2yNU4xOzFzIN88US=>
NCI-H345NVXxb5pUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHqy[oVKSzVyPUKxMlA3PDNizszN
RPMI-6666MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWfJR|UxRTJzLkO2NFIh|ryP
GR-STMlmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUXJR|UxRTJzLkSxO{DPxE1?
CHP-126Mlj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml:0TWM2OD1{MT62NVgyKM7:TR?=
EHEBMXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYjJR|UxRTJzLk[3N|Eh|ryP
CPC-NNFj6U|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHyzZo5KSzVyPUK0MlAzODFizszN
NB1MlHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXrJR|UxRTJ2Lk[5N|kh|ryP
LS-123MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH;MXJBKSzVyPUK0MlkxOTJizszN
ST486MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUTmemJrUUN3ME2yOU4yOTF|IN88US=>
NCI-H1963NHnCdZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX\JR|UxRTJ4LkC2NlMh|ryP
U-87-MGNVTCZnRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkTvTWM2OD1{Nj63OlQ1KM7:TR?=
COR-L279M17pbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mo\KTWM2OD1{Nj63PVIzKM7:TR?=
LU-165MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlXoTWM2OD1{OD6wPFYyKM7:TR?=
COLO-800NVnRVm95T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHjyXIFKSzVyPUK4MlI6PTZizszN
ETK-1MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTJ6LkO0OFYh|ryP
LNCaP-Clone-FGCMUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHj6blhKSzVyPUK5MlkzQDFizszN
SIG-M5M13UPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4PaTmlEPTB;M{CuO|k2OiEQvF2=
NB6MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYnJR|UxRTNyLkm1NFMh|ryP
NCI-H2107MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYfpNXpYUUN3ME2zNU4zOzN6IN88US=>
SNU-C1MnHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEfCZ3ZKSzVyPUOxMlMyOjZizszN
JARMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnrRTWM2OD1|MT6zO|k6KM7:TR?=
L-363MlfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4XzZ2lEPTB;M{KuNlE1PCEQvF2=
EW-24NW\ieFl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYXJR|UxRTN{LkO0O|Qh|ryP
NB69MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2nJV2lEPTB;M{OuOlQ2PCEQvF2=
EW-13MkXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFLaTIRKSzVyPUOzMlg6PjlizszN
Ramos-2G6-4C10NWjXcoFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWjJR|UxRTN2LkK5PVMh|ryP
TE-11NVmzTWs1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFrJW4pKSzVyPUO0MlQ5OjJizszN
L-428NVjBTm5DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlnXTWM2OD1|ND63OVM3KM7:TR?=
KP-N-YNMnzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXfJR|UxRTN2LkmwOVch|ryP
CGTH-W-1MnfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlHzTWM2OD1|Nj65NFQ5KM7:TR?=
K-562Mm[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVvJR|UxRTN5LkC4OlQh|ryP
NCI-H1299M1P5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoLVTWM2OD1|OD6xOlA{KM7:TR?=
RCC10RGBMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3jOZWlEPTB;M{iuNlA5OyEQvF2=
NCI-SNU-16MoLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3G4cWlEPTB;M{iuOVY2OyEQvF2=
LC-2-adMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVLJR|UxRTN7LkSzN|ch|ryP
MHH-PREB-1M2TqXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYXtSFVwUUN3ME2zPU44Ozh6IN88US=>
NCI-H64NGTkXXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnfuTWM2OD12MD6wPVQ5KM7:TR?=
LB996-RCCNILUR3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4TF[mlEPTB;NECuPFcyPiEQvF2=
DELM2PPR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXjsfJl3UUN3ME20NU41PDB3IN88US=>
MLMAM2\UN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFi5TZdKSzVyPUSxMlc2QTVizszN
SBC-1M1vFUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1\STGlEPTB;NEKuNVgxPiEQvF2=
MPP-89NGfqVYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHSyc45KSzVyPUSyMlU5PzVizszN
MV-4-11M2rBUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NULwT3F5UUN3ME20Nk46ODZ5IN88US=>
EoL-1-MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGnwRmpKSzVyPUS0MlE2PjhizszN
CW-2NEjvUHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUjJR|UxRTR2LkizOFIh|ryP
HTMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUfJR|UxRTR3LkewNFch|ryP
SW954MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHfFS3pKSzVyPUS3MlQyOjhizszN
A3-KAWNYPtUpZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYTJR|UxRTR7LkiwOlEh|ryP
TC-YIKNXmxbpFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3rZTWlEPTB;NUCuNFM3OyEQvF2=
SW962NHjrWGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkLQTWM2OD13ND64N|U4KM7:TR?=
KP-N-RT-BM-1NFTtXFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV;JR|UxRTV4Lk[2N|gh|ryP
NCI-H1395M1rCdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1y0U2lEPTB;NUiuPFE4OiEQvF2=
RPMI-8402NIHV[4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXfJR|UxRTV6Lkm1NlYh|ryP
SCHM361WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHnnT5dKSzVyPU[wMlk3OzhizszN
NCI-H2196NUL1WIdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoTlTWM2OD14MT6yN|Eh|ryP
LOXIMVIMVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVnJR|UxRTZzLkiyOlYh|ryP
TGBC24TKBM4TNfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFTmfGZKSzVyPU[yMlE1QTFizszN
SK-MEL-2M4fPWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVXJR|UxRTZ|Lkm4PVIh|ryP
U-698-MMXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF\sXGpKSzVyPU[4MlU3QDdizszN
NCI-H1522MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFzDZZNKSzVyPU[5MlAxPDdizszN
UACC-812MmrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEfCTWFKSzVyPU[5MlUzODlizszN
MHH-CALL-2NIPsSW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{XvNmlEPTB;N{CuNFYh|ryP
NB5NWPLUod6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFX1fXRKSzVyPUewMlM1PjhizszN
KARPAS-299MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoLhTWM2OD15MD60OFQ4KM7:TR?=
NCI-H1694M{DwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnfrTWM2OD15MT6wN|Ih|ryP
NCI-H82MnPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVfJR|UxRTdzLkm1NFch|ryP
SCC-15M4HYd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFfLRphKSzVyPUeyMlM1KM7:TR?=
NCI-H1436Mmf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4XOeWlEPTB;N{KuO|Q2PiEQvF2=
ATN-1MlfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFXKXodKSzVyPUe0MlUxPSEQvF2=
RPMI-8866MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1XodWlEPTB;N{SuO|UxQSEQvF2=
HCC1599M{\SV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVfDbIFwUUN3ME23OE45PzN{IN88US=>
NCI-H1155NHLzcW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIXCO2JKSzVyPUe0Mlk{PjdizszN
DOHH-2MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MU\JR|UxRTd2Lkm1NVQh|ryP
SK-NEP-1NEPrdmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnfTTWM2OD15NT6wO|U1KM7:TR?=
HCC1187NXPnSnN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFntcGtKSzVyPUe3MlYyOjJizszN
NCI-H322MMmf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M13jWWlEPTB;N{iuN|cxQSEQvF2=
NCI-H526NXT6SVJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV7JR|UxRTd6LkW4O|ch|ryP
NCI-H2171MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmXxTWM2OD15OT60NVM3KM7:TR?=
COLO-668M3zzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnnUTWM2OD16MT61PFg1KM7:TR?=
RS4-11M3HqUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTh{LkK1NFUh|ryP
NCI-H716NHPVNYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHfNXGFKSzVyPUiyMlkxPzVizszN
LU-134-ANWe4SmVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3:3T2lEPTB;OEOuNVM2OSEQvF2=
RPMI-8226MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{SzU2lEPTB;OESuNlExPyEQvF2=
KY821NFyxOXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlfyTWM2OD17MT62OVUyKM7:TR?=
ECC4MnHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1;rbWlEPTB;OUOuPFI3QSEQvF2=
EW-3NYPYZlFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\TWGlEPTB;OUSuPVA5OSEQvF2=
NB7NHLFcFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWPJR|UxRTl3Lke3PFYh|ryP
NCI-H720M2LYe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnT5TWM2OD17OD60NFYyKM7:TR?=
NCI-H446NFPXTIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2HMUGlEPTB;OUmuO|U5QCEQvF2=
NCI-H889NUDJXFlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWHJR|UxRTFyND6yOFIh|ryP
EW-22M2LweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4LaS2lEPTB;MUC2MlE6KM7:TR?=
BV-173NXL6XYZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml\0TWM2OD1zMEiuO|I5KM7:TR?=
WSU-NHLNUXuPJIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3jRPGlEPTB;MUC5MlY4OSEQvF2=
MN-60NGH3XnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoO1TWM2OD1zMEmuOlkh|ryP
DG-75NWjZbmVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlLmTWM2OD1zMUOuN|UzKM7:TR?=
DMS-79NWjQTJBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlnRTWM2OD1zMUeuN|gzKM7:TR?=
SK-MEL-1Ml;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoO1TWM2OD1zMUiuNFA6KM7:TR?=
DMS-153MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFPDOXZKSzVyPUGyNU44PDVizszN
NCI-H510ANEnwVYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHHEdnhKSzVyPUGyO{4{OiEQvF2=
BE-13MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1KzeGlEPTB;MUO0MlA1PCEQvF2=
KP-N-YSMmD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGXDVXhKSzVyPUGzPU44OzZizszN
SUP-T1M1;ufmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWfJR|UxRTF2Mz63NFgh|ryP
EW-12NH;tPWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFzIS2FKSzVyPUG0OE43QTlizszN
NB14M2XjSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkT5TWM2OD1zNEeuNFgzKM7:TR?=
MDA-MB-134-VINGLhRXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml\ETWM2OD1zNEiuNlY5KM7:TR?=
NCI-H1770NYntOo45T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIPzUIpKSzVyPUG1Ok4zPzlizszN
TURMoTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWLLeWdvUUN3ME2xOlcvQDdizszN
NCI-H1417MkjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{PCZmlEPTB;MUiwMlM{OSEQvF2=
IMR-5M3G4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmLnTWM2OD1zOEGuOVcyKM7:TR?=
NCI-H226NX3LfodFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVrJR|UxRTF6OD64OlYh|ryP
NCI-H187M4rXcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWPLOoU4UUN3ME2xPVAvODZ2IN88US=>
SF539NVjwSIVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYDJR|UxRTF7Mj63Nlgh|ryP
TALL-1MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX;JR|UxRTF7OD6zNFQh|ryP
TE-441-TMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2DkXmlEPTB;MUm5Mlc{QSEQvF2=
REHMUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{fNRWlEPTB;MkO2MlYzPiEQvF2=
MS-1Mn;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3zZOGlEPTB;MkO5MlEzOSEQvF2=
THP-1NWf2WG1WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXrNcmtZUUN3ME2yOlQvPzN6IN88US=>
NCI-H1838MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{noRmlEPTB;MkexMlQ2PiEQvF2=
P30-OHKMWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnTZTWM2OD1{OEOuPFQ4KM7:TR?=
C8166MmftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mkf3TWM2OD1|NEWuN|M5KM7:TR?=

... Click to View More Cell Line Experimental Data

In vivo Administration of MG-132 effectively rescues the expression levels and plasma membrane localization of dystrophin, β-dystroglycan, α-bdystroglycan, and α-sarcoglycan in skeletal muscle fibers from mdx mice, reduces muscle membrane damage, and ameliorates the histopathological signs of muscular dystrophy. [7] MG-132 treatment significantly reduces immobilization-induced skeletal muscle atrophy in mice, by downregulating the muscle-specific ubiquitin ligases atrogin-1/MAFbx and MuRF-1 mRNA. [8]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

Measurement of inhibitory activities of MG-132 against 20S proteasome The reaction mixture for the 20S proteasome inhibitory assay contains 0.1 M Tris-acetate, pH 7.0, 20S proteasome, MG-132, and 25 μM substrate dissolved in dimethyl sulfoxide in a final volume of 1 mL. After incuba tion at 37 °C for 15 minutes, the reaction is stopped by the addition of 0.1 mL of 10% SDS and 0.9 mL of 0.1M Tris acetate, pH 9.0. The fluorescence of the reaction products is measured. To determine the IC50 against 20S proteasome, various concentrations of MG-132 are included in the assay mixture.

Cell Assay:

[3]

Cell lines KIM-2, HC11, and ES
Concentrations Dissolved in DMSO, final concentrations ~25 μM
Incubation Time 24, and 48 hours
Method

Cells are exposed to various concentrations of MG-132 for 24, and 48 hours. Supernatant and monolayer cells are harvested by centrifugation and fixed in 70% ethanol in PBS for staining with acridine orange. Equal volumes of cells and acridine orange (5 mg/mL in PBS) are mixed on a microscope slide and examined by fluorescence microscopy. For annexin V analysis, cells are harvested by centrifugation and stained with annexin V and propidium iodide. For cell cycle analysis, cells are rehydrated in PBS at room temperature for 10 minutes, followed by staining with propidium iodide (5 mg/mL). All samples are analyzed using a Coulter Epics XL flow cytometer.

Animal Study:

[7]

Animal Models Male mdx (C57BL/10ScSn DMD mdx) mice
Formulation Dissolved in DMSO, and diluted in PBS
Dosages ~10 μg/kg/day
Administration Injection

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Tsubuki S, et al. J Biochem, 1996, 119(3), 572-576.

[2] Fiedler MA, et al. Am J Respir Cell Mol Biol, 1998, 19(2), 259-268.

view more

Chemical Information

Download MG-132 SDF
Molecular Weight (MW) 475.62
Formula

C26H41N3O5

CAS No. 133407-82-6
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 95 mg/mL (199.73 mM)
Ethanol 95 mg/mL (199.73 mM)
Water <1 mg/mL (<1 mM)
In vivo 1% DMSO/30% polyethylene glycol/1% Tween 80, pH 4 6 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name benzyl (S)-4-methyl-1-((S)-4-methyl-1-((S)-4-methyl-1-oxopentan-2-ylamino)-1-oxopentan-2-ylamino)-1-oxopentan-2-ylcarbamate

Customer Product Validation (6)


Click to enlarge
Rating
Source Nucleic Acids Res 2014 42(1), 458-74. MG-132 purchased from Selleck
Method Western blot
Cell Lines HeLa cells
Concentrations 20 uM
Incubation Time 8 h
Results As RMND5A downregulation resulted in a rapid decrease of protein Exportin-5, this effect was partially abolished by the proteasome inhibitor MG132, indicating that RMND5A protect Exportin-5 protein against proteasome degradation.

Click to enlarge
Rating
Source Nucleic Acids Res 2014 42(1), 458-74. MG-132 purchased from Selleck
Method Immunocytochemistry
Cell Lines HeLa cells
Concentrations 20 uM
Incubation Time 8 h
Results It was surprised to observe that Exportin-5 retention in nucleus when its protein levels were downregulated by RMND5A siRNA or miR-138. The proteasome inhibitor MG132 could recover not only Exportin-5 protein levels but also its normal subcellular localization.

Click to enlarge
Rating
Source EMBO Mol Med 2013 5, 397-412. MG-132 purchased from Selleck
Method Western Blot
Cell Lines MEF cells
Concentrations 30 uM
Incubation Time 6 h
Results Treatment of MEF with proteasome inhibitor MG132 resulted in similar increase of steady state levels of intracellular ATZ in both GFP- and TFEB- transfected Cells.

Click to enlarge
Rating
Source Plant Physiol 2012 60(1), 118-34. MG-132 purchased from Selleck
Method Immunoblot analysis
Cell Lines Arabidopsis thaliana
Concentrations 100 uM
Incubation Time 12 h
Results These rates of loss were markedly slower in the lrb1-1 lrb2-1 background. Importantly, phyB breakdown was also substantially attenuated upon exposing wild-type seedlings to the proteasome inhibitor MG132, thus implicating the 26S proteasome in particular. MG132 treatment also slightly stabilized phyB levels in lrb1-1 lrb2-1 seedlings, implying that other factors besides LRB1 and LRB2 might also direct phyB breakdown.

Click to enlarge
Rating
Source FEBS Lett 2012 586, 3787–3792. MG-132 purchased from Selleck
Method Western Blot
Cell Lines Hela cells
Concentrations
Incubation Time 12 h
Results When GSK-3 (Ser9) degradation was blocked by proteasome inhibitor (MG132), the increased amount of phosphorylated GSK-3 (Ser9) in responding to NOK was more clearly observed in the HeLa-NOK-HA cells (Fig. C).

Click to enlarge
Rating
Source 2012 Dr. Edison DUKE-NUS Graduate Medical School Singapore.. MG-132 purchased from Selleck
Method Western blot
Cell Lines NIH3T3 cells
Concentrations 25 μM
Incubation Time 1-4 h
Results By adding MG132, a proteasome inhibitor, the degradation of Per2 was dramatically decreased within 4 hours treatment.

Product Use Citation (40)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Proteasome Products

  • PI-1840

    PI-1840 is a reversible and selective chymotrypsin-like (CT-L) inhibitor with IC50 of 27 nM with little effects on the other two major proteasome proteolytic activities, trypsin-like (T-L) and postglutamyl-peptide-hydrolysis-like (PGPH-L).

  • SB-3CT

    SB-3CT is an effective and selective gelatinase inhibitor with Ki of 13.9 nM and 600 nM for MMP-2 and MMP-9, respectively.

  • Leupeptin Hemisulfate

    Leupeptin Hemisulfate is a reversible inhibitor of serine and cysteine proteases.

  • Bortezomib (PS-341)

    Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM in a cell-free assay.

  • Carfilzomib (PR-171)

    Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L act

  • Ixazomib (MLN2238)

    MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteoly

    Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.

  • MLN9708

    MLN9708 immediately hydrolyzed to MLN2238, the biologically active form, on exposure to aqueous solutions or plasma. MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM

    Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.

  • ONX-0914 (PR-957)

    ONX-0914 (PR-957) is a potent and selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome in a cell-free assay.

    Features:The first highly selective, small molecule inhibitor of the immunoproteasome. Potential use in cancer and autoimmune diseases (e.g. rheumatoid arthritis, inflammatory bowel disease, and lupus).

  • Celastrol

    Celastrol is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM.

    Features:A potent antioxidant and anti-inflammatory drug.

  • Oprozomib (ONX 0912)

    Oprozomib (ONX 0912) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. Phase 1/2.

Recently Viewed Items

Tags: buy MG-132 | MG-132 supplier | purchase MG-132 | MG-132 cost | MG-132 manufacturer | order MG-132 | MG-132 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description
Contact Us